Citadel Advisors
AUGX

Citadel Advisors’s Augmedix, Inc. Common Stock AUGX Stock Holding History

Citadel Advisors’s Portfolio AUGX Stock Details AUGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,850,000
Closed -$1.63M – 15537
2024
Q2 		$1.63M Sell
1,850,000
-39,076
-2% -$80.6K ﹤0.01% 5701
2024
Q1 		$7.73M Buy
1,889,076
+1,817,233
+2,529% +$8.13M ﹤0.01% 3302
2023
Q4 		$420K Buy
71,843
+52,211
+266% +$275K ﹤0.01% 8468
2023
Q3 		$101K Sell
19,632
-48,924
-71% -$230K ﹤0.01% 10884
2023
Q2 		$330K Buy
68,556
+58,015
+550% +$201K ﹤0.01% 8839
2023
Q1 		$18.3K Buy
+10,541
New +$17.2K ﹤0.01% 13128
2022
Q4 		– Sell
-23,090
Closed -$33K – 15596
2022
Q3 		$33K Buy
+23,090
New +$39.6K ﹤0.01% 11858
2022
Q1 		– Sell
-26,989
Closed -$85K – 14808
2021
Q4 		$85K Buy
+26,989
New +$97.8K ﹤0.01% 12881

Other funds holding AUGX

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
SM
Samjo Management New York $231M AUM 13.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Citadel Advisors's AUGX Position: Q3 2024 in Review

Citadel Advisors sold out of Augmedix, Inc. Common Stock (AUGX) in Q3 2024, closing a stake of 1,850,000 shares — an estimated $1.63M sold.

Citadel Advisors first reported a position in AUGX in Q4 2021 and held it in 8 quarters. The position peaked at $7.73M in Q1 2024. 45 funds tracked by Wall St. Rank hold AUGX as of Q3 2024.

  • Citadel Advisors reported no remaining Augmedix, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Citadel Advisors sold 1,850,000 Augmedix, Inc. Common Stock shares in Q3 2024, an estimated $1.63M.
  • Citadel Advisors first reported a position in Augmedix, Inc. Common Stock in Q4 2021 and held it in 8 quarters.
  • Citadel Advisors's Augmedix, Inc. Common Stock position peaked at $7.73M in Q1 2024.
  • 45 funds tracked by Wall St. Rank held Augmedix, Inc. Common Stock as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.